Genomic Analysis Core

项目摘要 基因组分析核心结合了NCI CCSG支持的两个机构的专业知识和仪器， DNA测序设施和基因组学设施，为DNA提供综合服务 测序和分子图谱。塔潘·甘古利博士，DNA测序设施主任，自 2003年，已被任命为综合核心董事。两种共享资源的整合 为艾布拉姆森癌症中心(ACC)成员提供更高效的途径和更清晰的技术。它还 提供机会，通过更好的协调和提高服务的质量和范围 最大限度地提高资源利用率，而不会重复。一支经验丰富、训练有素的专业团队 Under Two技术总监提供全方位的基因组和分子生物学服务。这些 对于ACC成员来说，研究特定基因在正常或异常细胞中的作用是必不可少的服务 在癌细胞和肿瘤中发现的过程。研究人员能够观察全球基因表达模式 在样本中，以及在未受影响或肿瘤基因组中的遗传变异性。核心在以下方面提供排序服务 两个平台，ABI毛细管测序仪上的金标准桑格测序，以及半导体测序 关于离子激流PGM及其升级，质子。毛细管测序仪还可以进行微卫星基因分型 和片段分析。全基因组和靶向分子图谱在多个平台上进行。 核心支持在Affymetrix GeneChips、Luminex FlexMap 3D、Fluidigm上进行定量RNA分析 BioMark HD和ABI 7900实时聚合酶链式反应系统，而DNA图谱可在Affymetrix SNP上获得 基因芯片、Fluidigm BioMark HD和ABI 7900。分子生物学服务包括克隆、亚克隆 构建小鼠基因打靶的打靶载体。行政协调会成员受益于协商和 培训贯穿于他们的整个项目。服务范围以及核心主管的专业知识 促进基因发现、功能表征和其他研究问题，以阐明分子 人类癌症的发病机制。此外，DNA和RNA的分子图谱以及靶向 癌症基因测序可以帮助ACC成员进行癌症诊断、亚分类、风险预测 选择合适的治疗方法。117个行政协调会成员在本报告所述期间使用了核心系统(10/01/13- 09/30/14)，占核心总使用量的36%。CCSG支持占提议核心的15% 预算，剩余资金来自按存储容量使用计费、赠款/合同和机构支助。 额外的机构支持以购买设备的资金形式提供。

Project Summary The Genomic Analysis Core combines the expertise and instrumentation of two NCI CCSG supported facilities, the DNA Sequencing Facility and the Genomics Facility, to provide an integrated array of services for DNA sequencing and molecular profiling. Tapan Ganguly, PhD, the Director of the DNA Sequencing Facility since 2003, has been appointed Director of the consolidated Core. The integration of the two Shared Resources provides more efficient access and clarity of technologies to Abramson Cancer Center (ACC) members. It also presents opportunities for enhancing the quality and the range of services with better coordination as well as maximizing resource utilization without duplication. A team of highly experienced and trained professionals under two Technical Directors provides a whole spectrum of genomic and molecular biological services. These services are essential to ACC members for studying the role of specific genes in normal or abnormal cellular processes found in cancer cells and tumors. Investigators are able to observe global gene expression pattern in a sample, and genetic variability in an unaffected or tumor genome. The Core offers sequencing service on two platforms, gold standard Sanger sequencing on ABI capillary sequencers, and semiconductor sequencing on Ion Torrent PGM and its upgrade, Proton. The capillary sequencers also enable microsatellite genotyping and fragment analysis. Whole genome and targeted molecular profiling are performed on multiple platforms. The Core supports quantitative RNA profiling on Affymetrix GeneChips, Luminex FlexMap 3D, Fluidigm BioMark HD, and ABI 7900 real-time PCR system while DNA profiling is available on Affymetrix SNP GeneChip, Fluidigm BioMark HD and ABI 7900. The molecular biological services include cloning, subcloning and targeting vector construction for gene targeting in mice. ACC members benefit from consultations and training available throughout their projects. The range of services along with the expertise of the Core Director facilitates gene discovery, functional characterization and other research questions to elucidate the molecular pathogenesis of human cancers. In addition, molecular profiling of DNA and RNA together with targeted sequencing of cancer genes can help ACC members in cancer diagnosis, subclassifications, risk prediction and selection of appropriate therapy. 117 ACC members used the Core in the reporting period (10/01/13- 09/30/14) representing 36% of the total Core usage. CCSG support accounts for 15% of the proposed Core budget with the remaining funding coming from chargebacks, grants/contracts and Institutional support. Additional Institutional support comes in the form of funding for equipment purchase.